MelaFind(R) Results Improve Detection of Melanoma, Study Shows

Study Published in Archives of Dermatology Shows Significant Impact of MelaFind on Detection of Melanoma

MelaFind, developed by MELA Sciences, Inc. (NASDAQ: MELA - News), was shown to improve melanoma detection in a study of 179 dermatologists. The average sensitivity of dermatologists before obtaining the MelaFind output was 69 percent, and the average sensitivity after obtaining the MelaFind output was 94 percent, according to a recent study published online in the Archives of Dermatology on February 20, 2012.

MelaFind, a non-invasive, multi-spectral computer vision system recently approved by the FDA, uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin.

Cepheid Reports Fourth Quarter and Full Year 2011 Results

Record GeneXpert® System Placements Contribute to 39% Growth in Clinical Business

Cepheid (Nasdaq: CPHD - News) today reported revenue for the fourth quarter of 2011 of $80.1 million.  Net loss was $1.6 million, or $(0.03) per share, which compares to revenue of $58.7 million and net income of $1.3 million, or $0.02 per diluted share, in the fourth quarter of 2010.  As anticipated, the fourth quarter net loss reflected a one-time, non-cash charge to cost of sales of $5.4 million, or $0.08 per share, associated with the termination of a patent license.

Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome

Company to Webcast Conference Call and Presentation to Discuss Results of Clinical Validation Study Published in Genetics in Medicine

Sequenom, Inc. (NASDAQ:SQNM - News), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM),  launched its noninvasive proprietary MaterniT21 laboratory developed  test (LDT). The MaterniT21 LDT detects a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome. The test is now available to physicians upon request in 20 major metropolitan regions across the United States.

PerkinElmer to Acquire Caliper Life Sciences for Approximately $600 Million

Transaction enhances global leadership position in molecular imaging and detection for Human and Environmental Health

--Creates opportunity to significantly expand global delivery of compelling customer solutions in a broad range of high-growth end markets
--Combined R&D expertise and intellectual property to accelerate innovation

PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that it has signed a definitive agreement to acquire Caliper Life Sciences, Inc. (NASDAQ: CALP), a Hopkinton, Massachusetts-based leader in imaging and detection solutions for life sciences research, diagnostics and environmental markets, for $10.50 per share, for a total net purchase price of approximately $600 million in cash.